Boyds Awarded Queen’s Award for Enterprise
Product News Apr 24, 2018
Professor Alan Boyd
Boyds, a leading consultancy business supporting the development of pharmaceutical and biotech products and devices for patient benefit, has today been recognised with one of the UK’s most prestigious business awards – The Queen’s Award for Enterprise, International Trade for Outstanding Short Term Growth in overseas sales for the last three years.
Boyds was established 13 years ago, and now employs 10 members of staff working out of its offices in Cheshire and Cambridgeshire.
Working with small pharmaceutical and biotechnology companies as well as medical departments at universities, the team at Boyds helps to translate research ideas into medicines to treat human diseases. The business provides a range of expertise and skills central to the development of these medicinal products.
The Award has been made in recognition for the Boyds’ work, particularly in supporting the development of cell and gene therapies, as well as providing the expertise and skills necessary to the international development of other pharmaceutical and biotechnology products. Boyds’ expert assistance helps to expedite the development of medicines, adding value to these products, and helping businesses reach key milestones in their drug development projects.
This expertise is of a very high calibre, as demonstrated by the number of medicinal products that Professor Boyd and his team have worked on over his career and that are now prescription medicines that are available on a worldwide basis. Because of this, the team at Boyds is regularly called upon to help and support many fledgling ideas for new medicines in various organisations and companies outside of the UK.
Working in a highly regulated global industry, Boyds has grown its overseas sales by two thirds in the last three years with profits more than doubling.
Founder and CEO, Professor Alan Boyd commented, “It is a tremendous honour for Boyds to be recognised with the prestigious Queen’s Award for Enterprise. The development of medicines for patient benefit is a global business, and Boyds works internationally to support the development of drugs and medical devices.”
He continues, “Our clients are located in the major markets for pharmaceutical development and commercialisation. We also work for companies and academic institutions that are located in countries that have a strong science and medical base and whose government encourages entrepreneurship to help SME development. Around 60% of our revenue now comes from businesses based outside the UK, and we anticipate this trend will continue.”